Understanding Post-Stroke Fatigue: Why Do Patients Get Tired Easily?

Tissue plasminogen activator (tPA) is a medication administered to stroke patients to break up blood clots and restore blood flow to the brain. tPA is a powerful clot-clearing drug that can be life-saving for patients with acute ischemic strokes, which are caused by blood clots interrupting blood flow to the brain. However, not all stroke patients receive this treatment, and there are several reasons for this. Firstly, many hospitals lack the necessary resources and expertise to rapidly administer tPA. Additionally, tPA carries a risk of hemorrhage, and some emergency physicians may be reluctant to make the call to administer it. Furthermore, tPA is only used for ischemic strokes and not for hemorrhagic strokes, where it would worsen bleeding. This article will explore the reasons why stroke patients may or may not receive tPA treatment and discuss the benefits and risks associated with its use.

tPA is a medication that can break up blood clots and restore blood flow to the brain

Tissue plasminogen activator (tPA) is a medication used to break up blood clots and restore blood flow to the brain. It is a thrombolytic drug, meaning it can dissolve blood clots. tPA is used to treat ischemic strokes, which occur when a blood clot blocks blood flow to the brain. This can lead to tissue death, brain damage, disability, and death.

TPA works by activating the enzyme plasminogen, converting it into plasmin. Plasmin breaks down the links between fibrin molecules in blood clots, dissolving them. This helps to restore blood flow to the brain and limit the risk of damage and impairment from a stroke.

TPA must be administered within a few hours of the onset of stroke symptoms to be effective. The American Stroke Association recommends administering tPA within 4.5 hours of a stroke for the best outcomes. However, faster treatment, ideally within the first 3 hours, is associated with reduced complications.

While tPA has been shown to be effective in treating strokes, there are risks and side effects associated with its use. It is a powerful blood thinner, and serious side effects may include bleeding in the brain, digestive system, or other areas of the body.

tPA is not suitable for all stroke patients and can have serious side effects

Tissue plasminogen activator (tPA) is a powerful blood-thinning medication that can save the lives of stroke patients by dissolving blood clots and restoring blood flow to the brain. However, tPA is not suitable for all stroke patients and can have serious side effects.

TPA is only used for ischemic strokes, the most common type, which occur when a blood clot cuts off the blood supply to part of the brain. It is not used for hemorrhagic strokes, which occur when a weakened blood vessel in or around the brain ruptures and bleeds into the brain. Using tPA in hemorrhagic strokes would worsen the bleeding.

Even in ischemic strokes, the use of tPA is not entirely risk-free. As a clot-dissolving medicine, tPA can increase the risk of bleeding into the brain. While the benefit-to-risk ratio is generally favourable, serious side effects may still occur in a small percentage of patients. These include intracranial bleeding, digestive system hemorrhage, severe blood loss, and minor bleeding in the gums or nose.

Furthermore, tPA is contraindicated in certain patient groups, such as those who have recently undergone major surgery, are taking blood-thinning medication, or have low blood counts. Administering tPA to these patients could lead to an increased risk of bleeding. Additionally, patients over the age of 80, those with a history of diabetes or prior stroke, and those taking oral anticoagulants may not be suitable candidates for tPA treatment.

The timely administration of tPA is also crucial. It is most effective when given within 90 minutes to 3 hours after the onset of stroke symptoms, and the national standard is to aim for a door-to-needle time of 60 minutes. Beyond 4.5 hours, tPA administration is not recommended as it may increase the risk of death.

tPA is most effective when administered within 3 hours of the onset of stroke symptoms

The effectiveness of tPA in treating ischemic stroke is highly dependent on the time elapsed since the onset of stroke symptoms. tPA is a thrombolytic agent that breaks up blood clots and restores blood flow to the brain, thereby limiting the risk of brain damage and disability. The American Stroke Association (ASA) recommends administering tPA within 4.5 hours of the stroke, but it is most effective when given within the first 3 hours.

The benefit of tPA treatment decreases as time passes, with the best outcomes observed when treatment is administered within 1.5 hours of symptom onset, followed by treatment within 1.5 to 3 hours, and then within 3 to 4.5 hours. The American Heart Association/American Stroke Association (AHA/ASA) and The Joint Commission (TJC) advocate for a door-to-needle time of 60 minutes for IV tPA administration.

The effectiveness of tPA within the 3-hour window is supported by several clinical trials, including the National Institute of Neurological Disorders and Stroke (NINDS) trial, which showed improved neurological outcomes when IV tPA was given within 3 hours of symptom onset, with the best outcomes observed within 90 minutes. The European Cooperative Acute Stroke Study III (ECASS-III) further supported the use of tPA within the 3-hour window, demonstrating a significant improvement in clinical outcomes.

While there is strong evidence supporting the timely use of tPA, it remains underutilized. Efforts to increase utilization include raising public awareness about stroke signs and the importance of seeking immediate medical attention. Additionally, the expansion of the therapeutic time window to 4.5 hours has been endorsed by major professional organizations, although it remains off-label in the United States.

The underutilization of tPA within the critical 3-hour window can be attributed to various factors, including delays in activating emergency medical services, suboptimal hospital infrastructure, medical contraindications, and the narrow therapeutic time window. Nevertheless, tPA remains a powerful treatment option for ischemic stroke when administered promptly, offering a 10:1 benefit-to-harm ratio.

The American Stroke Association strongly endorses giving tPA to eligible patients

However, the use of tPA remains controversial within the broader medical community, particularly among emergency physicians. Some emergency physicians are reluctant to administer tPA due to its associated risks, including a 6% risk of hemorrhage. There may also be a lack of understanding among emergency physicians about the historical "building blocks" that have led neurologists to view tPA as an effective treatment for acute ischemic stroke.

To ensure the best outcome for patients, it is crucial that hospitals have stroke teams in place that can rapidly evaluate and treat patients with tPA within the recommended timeframe. Additionally, further efforts are needed to bridge the gap between neurologists and other medical professionals, such as through shared conceptualizations of completed trials and the intellectual tradition from which they emerged.

tPA is not always readily available in hospitals

Secondly, not all hospitals are equipped to rapidly administer tPA. Many hospitals, particularly in rural areas, lack a dedicated stroke team that can ensure swift evaluation, diagnosis, and decision-making. This includes acquiring a CT scan and conducting the necessary lab studies before administering tPA. The presence of a stroke team improves the chances of timely and effective treatment.

Thirdly, tPA carries a risk of hemorrhage, and emergency physicians may be reluctant to make the call to administer it without the input of a neurologist. This can further delay the treatment process. Additionally, tPA is only used for ischemic strokes caused by blood clots and is not suitable for hemorrhagic strokes, which involve bleeding in the brain.

Furthermore, tPA has specific contraindications and is not suitable for all patients. It is not recommended for those who have recently undergone major surgery, are taking blood-thinning medication, or have low blood counts, as it increases the risk of bleeding. Other factors, such as elevated blood pressure, active internal bleeding, or the use of certain anticoagulants, may also contraindicate the use of tPA.

Lastly, the effectiveness of tPA also depends on the size of the blood clot. For larger blockages, a mechanical thrombectomy procedure may be required in addition to or instead of tPA administration. This involves threading a device through an artery to mechanically remove the clot.

Frequently asked questions